Type 2 diabetes trials recruiting in Indiana

All Type 2 diabetes trials nationally

Cities in Indiana

Recruiting trials in Indiana

• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
  NCT07662109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville
• A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
  NCT06112418 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
  NCT07061574 · Phase: Phase 1, Phase 2 · Ages: 9 Years to 20 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Valparaiso
• A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
  NCT07668388 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
  NCT07282613 · Phase: Phase 3 · Ages: 10 Years to 18 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
  NCT07340320 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Evansville
• A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
  NCT06739122 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Brownsburg
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville, Indianapolis, Valparaiso
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
  NCT07662213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Evansville
• AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
  NCT07797335 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · Indiana: Franklin, Greenfield, Muncie
• Denosumab for Type 1 Diabetes
  NCT06524960 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Indiana: Indianapolis
• Drug Interaction Potential of Pro-Inflammatory Conditions
  NCT07360938 · Phase: Not specified · Ages: 12 Years to 99 Years · Sex: All (male and female) · Indiana: Indianapolis
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Avon, Elkhart, Franklin, Greenfield
• Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
  NCT07579702 · Phase: Not applicable (e.g. observational or device study) · Ages: 14 Years to 75 Years · Sex: All (male and female) · Indiana: Indianapolis
• Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
  NCT07521475 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Bloomington
• GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
  NCT07228117 · Phase: Not applicable (e.g. observational or device study) · Ages: 7 Years to 85 Years · Sex: All (male and female) · Indiana: Indianapolis
• Heat Therapy in Type 2 Diabetes
  NCT06596967 · Phase: Phase 1 · Ages: 55 Years and older · Sex: All (male and female) · Indiana: West Lafayette
• Registry for Stage 2 Type 1 Diabetes
  NCT06481904 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Indiana: Indianapolis
• Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
  NCT07527650 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: South Bend